What Fragmin (Dalteparin) Treats: Main Uses and Benefits

Dalteparin is commonly used to help with conditions characterized by periods of heightened symptoms arising from blood clots in the veins, known as Venous Thromboembolism (VTE). It is considered relevant for managing conditions that involve established Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) in adults and pediatric patients. It is also relevant for easing symptoms associated with acute coronary stress, such as Unstable Angina and Non-Q-Wave Myocardial Infarction. The medication provides support that generally contributes to easing the overall symptom load and assists with maintaining functional stability during symptomatic periods.

The medicine is applied in scenarios where additional management of discomfort is required during high-risk phases, including following major surgeries (like hip or abdominal replacement), during extended periods of severely restricted mobility due to acute illness, and may assist with the risk of VTE recurrence in patients with cancer.

“It is considered relevant to support the patient during difficult episodes by easing distress and maintaining a sense of stability when symptoms are more noticeable.”

---

Quick Fact: Relief for Vascular Stress Dalteparin assists with managing symptoms related to vascular stress, which may help patients cope more steadily with symptom fluctuations.

The eligibility profile for Dalteparin (Fragmin) is strictly defined by regulatory authorities based on absolute prohibitions and population-specific restrictions.

Dalteparin is absolutely contraindicated (must not be used) in patients with active major bleeding, a documented history of Heparin-Induced Thrombocytopenia (HIT), or septic endocarditis. It is also prohibited for individuals with known hypersensitivity to the drug or other low molecular weight heparins. The use of high-dose Dalteparin is strictly forbidden when combined with neuraxial anesthesia (spinal/epidural).

Age Group	Eligibility Status
Adults	Established use.
Pediatric Patients	Approved from 1 month of age and older.
Infants < 1 month	Safety and efficacy not established.

Conditional eligibility applies to certain comorbidities. Use requires careful consideration and often monitoring in cases of severe renal impairment and severe hepatic impairment. Caution is necessary for patients with uncontrolled severe hypertension or recent surgery/injury to the central nervous system, eyes, or ears. During pregnancy, use may be permitted when the benefit is justified, but multi-dose vials containing benzyl alcohol are restricted. Use during lactation is recommended with caution.

Interactions with other medicines and products

Dalteparin sodium's official interaction profile is characterized primarily by Pharmacodynamic Reinforcement, which describes additive effects on the body’s blood clotting system. This interaction increases the risk of bleeding or hemorrhage when Dalteparin is co-administered with other agents that affect hemostasis, as documented in regulatory labeling.

Specific combinations are formally contraindicated by regulatory authorities. These include co-administration with Defibrotide and Mifepristone when used for pregnancy termination. Dalteparin is also contraindicated during neuraxial anesthesia or spinal puncture due to the risk of spinal or epidural hematomas.

Documented Pharmacodynamic Effects

The anticoagulant effect of Dalteparin may be enhanced by combining it with other Anticoagulants (such as Warfarin), Platelet Inhibitors (including Clopidogrel and Dipyridamole), and Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). Conversely, some substances may cause an antagonistic effect, leading to a reduction in the anticoagulant activity of Dalteparin. These include Antihistamines, certain Cardiac Glycosides, Tetracycline, and Ascorbic Acid.

There are no established interactions documented with food, alcohol, or most herbal products. A specific note exists for patients with renal failure when Dalteparin is used concomitantly with high dose ASA or NSAIDs, requiring particular care.

How Fragmin (Dalteparin) Works

The mechanism of Dalteparin is strictly focused on interfering with the coagulation cascade at the enzymatic level.

---

Catalytic Potentiation of Antithrombin III

Dalteparin initiates its action by binding with high affinity to the circulating protein Antithrombin III (AT III). This binding causes a crucial conformational change in AT III, transforming it into a more active inhibitor. The drug acts as a catalytic template, accelerating the activity of the body's intrinsic anticoagulant system. This enhancement allows for efficient downstream intervention in the coagulation pathway.

---

Selective Inhibition of Factor Xa

The potentiated AT III-Dalteparin complex selectively and efficiently targets Coagulation Factor Xa (FXa). Inactivating this pivotal enzyme arrests the central step in the common coagulation pathway, leading to impaired formation of Thrombin (FIIa). Due to its relatively short chain length, Dalteparin's mechanism is weighted towards inhibiting FXa, resulting in a functional suppression of coagulation.

---

Systemic Reduction in Fibrin Formation

The cascading molecular effect—primarily the inactivation of FXa—causes a systemic deficiency of active Thrombin. Since Thrombin is necessary to convert circulating Fibrinogen into the stabilizing Fibrin mesh, this mechanistic intervention effectively suppresses the final stage of clot construction. The physiological consequence is a reduction in the blood's intrinsic capacity to form stable clots.

Administration Overview

Fragmin (dalteparin) is a low molecular weight heparin administered via subcutaneous injection. This means the medication is delivered into the fatty tissue layer just beneath the skin, rather than into a muscle or vein. Proper administration technique is essential to ensure the medication is absorbed correctly and to minimize the risk of local irritation or bruising.

Preparation for Use

Before administration, the medication should be inspected visually. The liquid should be clear and colorless or slightly yellow. If the solution is cloudy or contains visible particles, it should not be used.

For those using pre-filled syringes, the air bubble in the syringe should not be expelled before the injection unless specifically required to achieve a partial dose. This bubble helps ensure the full delivery of the medication and helps prevent the drug from leaking back into the needle track.

Injection Site Selection

Commonly used injection sites include the fatty areas of the lower abdomen, at least two inches away from the navel. Alternatively, the upper outer thigh or the upper outer area of the buttocks may be used. It is important to rotate the injection site with each dose to maintain skin health and prevent the buildup of fibrous tissue.

Injection Technique

1. Clean the area: The chosen site should be cleaned with an alcohol swab and allowed to air dry.
2. Grasp the skin: A fold of skin should be gently pinched between the thumb and forefinger to create a stable area of fatty tissue.
3. Insert the needle: The needle is inserted at a 45-to-90-degree angle into the skin fold.
4. Inject the liquid: The plunger is depressed steadily until the syringe is empty.
5. Withdraw the needle: The needle is removed at the same angle it was inserted.
6. Apply pressure: Gentle pressure may be applied to the site with a piece of gauze, but the area should not be rubbed, as rubbing increases the likelihood of bruising.

Storage and Disposal

Fragmin should be stored at room temperature, away from excessive heat and moisture. Once an injection is complete, the needle and syringe must be disposed of immediately in a puncture-resistant sharps container. Syringes should never be reused or disposed of in regular household trash.

Research Evidence / Overview of Studies for Fragmin (Dalteparin)

---

1. Evidence for Preventing Blood Clots After Surgery

Research has been conducted to evaluate outcomes related to the formation of blood clots, or Venous Thromboembolism (VTE), following major surgical procedures. Studies conducted were primarily short-term Randomized Controlled Trials (RCTs) and comprehensive Meta-Analyses. These studies focused on patients undergoing high-risk procedures, such as abdominal surgery or total hip replacement surgery. The main outcomes studied included measurements of DVT and PE event rates, and the frequency of major bleeding events was also tracked as a comparative outcome.

Studies reported measurements of VTE event rates in the days and weeks following surgery, describing patterns that were observed when Dalteparin was compared to other standard treatments or sometimes to a placebo. Data for long-term outcomes remain insufficient, as follow-up durations were typically limited to the short period immediately after surgery and discharge.

2. Evidence for Preventing Blood Clots in Acutely Ill Medical Patients

Research concentrated on hospitalized adults who experienced severely restricted mobility due to acute medical conditions. The study design mainly involved large-scale, double-blind Randomized Controlled Trials that often compared Dalteparin to a placebo. These studies reported measurements of combined clinical outcomes, which included symptomatic DVT and PE, at a primary measurement point, typically around Day 21 of the study period.

Findings described patterns observed in the event rates between the groups. Studies also monitored all-cause mortality, which was often found to be highly influenced by the underlying acute medical illness. Evidence provides limited insight into long-term outcomes for VTE prevention after a patient is discharged. Subgroup findings are uncertain for specific acutely ill patient cohorts due to population heterogeneity.

3. Evidence for Managing Recurrent Blood Clots in Patients with Cancer

Dalteparin was evaluated in long-term Randomized Controlled Trials (RCTs) and Meta-Analyses for its role in extended treatment for VTE recurrence in adult patients with active cancer. Research explored the occurrence of VTE recurrence over a standard treatment duration, commonly six months. Findings describe patterns related to recurrence events, and the frequency of major bleeding was observed in comparison to other established treatments. Follow-up durations were primarily limited to this six-month period, meaning there is limited information for long-term outcomes beyond that timeframe.

Key Studies & References Treatment of Malignancy Associated Venous Thromboembolism (Referencing HOKUSAI VTE Cancer and SELECT-D Trials comparing Dalteparin to DOACs)

Common questions about Fragmin (Dalteparin) (FAQ)

Q: Will it make me sleepy or affect my driving?

A: Official product information, including regulatory documents, indicates that this medication may cause dizziness and somnolence (sleepiness). These effects are known to potentially impair a person's ability to drive or operate complex machinery. Patients are advised to use caution until they are aware of how the product affects them.

Q: Is it safe to use for a very long period (e.g., several years)?

A: Regulatory documents indicate that clinical trial data supporting the drug's efficacy for some specific uses has not been fully assessed for treatment periods longer than 12 weeks. Decisions regarding the long-term use of this medication should be made by a healthcare professional following an assessment of the potential risks and benefits based on the patient's individual circumstances.

Q: Is it safe for children who are 2 years old?

A: According to official prescribing information, this medication is indicated as an add-on therapy for certain types of partial-onset seizures in pediatric patients who are 1 month of age and older. Dosing is weight-dependent for pediatric use. However, for conditions other than those specified, the safety and effectiveness in this particular age group have not been fully established in regulatory data.

Q: Will this help me sleep better?

A: The medication is not approved or indicated for the treatment of sleep disorders. However, somnolence, the medical term for sleepiness, is reported in regulatory documents as one of the most common adverse reactions in adult patients. Patients with concerns about sleep should consult with a healthcare professional.

Storage and Disposal Requirements for Fragmin (Dalteparin)

Fragmin injection must be stored at room temperature, specifically below 25 C (77 F), and must not be frozen.

---

Storage Conditions

• Temperature: Store below 25 C (77 F). Do not freeze.
• Protection: Keep the product in its original package and protect it from light.
• Child Safety: The medication must be kept out of the sight and reach of children.

---

Stability and Disposal

Multi-dose vials must be discarded 14 days after the first needle entry. Solutions prepared for intravenous infusion should be used immediately.

All used syringes and needles are classified as sharps and must be disposed of in a dedicated, puncture-proof container. Unused or expired medicine must be discarded according to local requirements and must not be thrown away via wastewater or household waste.